Affimed Announces Receipt of Nasdaq Delisting Notice

Core Points - Affimed N.V. has received a notice from Nasdaq indicating that its common shares will be suspended from trading on May 20, 2025, due to insolvency filing and compliance concerns [1][2] - The company filed for insolvency in the local court of Mannheim, Germany, on May 13, 2025 [3] Company Overview - Affimed N.V. is a clinical-stage immuno-oncology company focused on harnessing the innate immune system to combat cancer through its proprietary innate cell engagers (ICE) [4] - The company is headquartered in Mannheim, Germany, and aims to develop therapies for various hematologic and solid tumors [4]